Formulation Development & Stability Testing

The contract entails the development of stable and scalable formulations for contraceptive candidates, with a strong emphasis on meeting rigorous scientific and regulatory standards. Work must follow ICH guidelines for stability testing to ensure product consistency, efficacy, and safety over time under varying environmental conditions. The project is structured as a subcontract under the National Institutes of Health, National Institute of Child Health and Human Development, part of the U.S. Department of Health and Human Services, and is assigned the NAICS code 325412, indicating focus on pharmaceutical preparation manufacturing. The solicitation was posted on April 28, 2026, with a firm deadline for responses set for May 28, 2026, at 8:00 PM, requiring timely submission of technical and operational proposals. Performance of the work is expected to align with federal pharmaceutical development protocols, though the specific location of performance is not designated. No set-aside provisions or small business preferences are specified, making this opportunity open to all qualified entities capable of delivering advanced pharmaceutical formulation capabilities.